KINIKSA PHARMACEUTICALS, LTD. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.33 USD | +0.35% |
|
+5.06% | +16.08% |
| Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
| Apr. 23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 389M | Sales 2025 * | 536M | Capitalization | 1.44B |
|---|---|---|---|---|---|
| Net income 2024 * | -7M | Net income 2025 * | 42M | EV / Sales 2024 * | 3.07 x |
| Net cash position 2024 * | 242M | Net cash position 2025 * | 386M | EV / Sales 2025 * | 1.96 x |
| P/E ratio 2024 * |
-190
x | P/E ratio 2025 * |
34.7
x | Employees | 297 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kiniksa Pharmaceuticals, Ltd.
More recommendations
More press releases
| 1 day | +0.35% | ||
| 1 week | +5.06% | ||
| Current month | +8.76% | ||
| 1 month | +14.83% | ||
| 3 months | +0.39% | ||
| 6 months | +41.68% | ||
| Current year | +16.08% |
1 week
19.62
20.44
1 month
16.5620.44
Current year
16.5622.09
1 year
13.0222.09
3 years
7.3622.09
5 years
5.0128.67
10 years
5.0132.88
| Managers | Title | Age | Since |
|---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 15-06-30 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 15-06-30 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-09-30 |
Barry Quart
BRD | Director/Board Member | 67 | 15-09-30 |
Thomas Malley
BRD | Director/Board Member | 55 | 16-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 20.36 | +0.49% | 128 138 |
| 24-05-08 | 20.26 | -0.34% | 272,503 |
| 24-05-07 | 20.33 | +1.70% | 332,862 |
| 24-05-06 | 19.99 | -0.45% | 296,252 |
| 24-05-03 | 20.08 | +3.61% | 403,855 |
Delayed Quote Nasdaq, May 09, 2024 at 01:59 pm EDT
More quotes
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
20.26
USD
Average target price
30.67
USD
Spread / Average Target
+51.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.08% | 1.44B | |
| +2.99% | 108B | |
| +10.28% | 105B | |
| +1.57% | 23.46B | |
| -12.22% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.64% | 17.19B | |
| +6.21% | 13.99B | |
| +36.73% | 12.53B |
- Stock Market
- Equities
- KNSA Stock